Exelixis initiates phase 3 trial of cabozantinib in advanced renal cell carcinoma

This article was originally published here

The primary endpoint of the trial is progression-free survival, and the secondary endpoints are overall survival and objective response rate. “Clinical observations suggest cabozantinib promotes an immune-permissive environment,

The post Exelixis initiates phase 3 trial of cabozantinib in advanced renal cell carcinoma appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply